Dr. Naveen Pemmaraju is Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center. He completed undergraduate studies with a Bachelor of Science cum laude in Cell and Molecular Biology at Tulane University. He received his medical degree at the University of Arkansas for Medical Sciences, completed Internal Medicine training at the Osler Medical Program of Johns Hopkins (Barker Firm), and completed a fellowship in Hematology/Oncology at MD Anderson Cancer Center.
Dr. Pemmaraju is board certified in Internal Medicine, Hematology and Oncology. He is a clinical investigator with clinical and research interests focused in the areas of analyzing patient characteristics and outcomes as well as development of novel therapies for patients with myeloproliferative neoplasms (MPN), acute myeloid leukemia (AML), and blastic plasmacytoid dendritic cell neoplasm (BPDCN). Dr. Pemmaraju has extensive experience with clinical trial design, enrollment of patients, and serving as the PI or co-PI of several enrolling and upcoming clinical trials at his institution. He has authored or co-authored over 100 scientific/medical publications in the peer-reviewed literature. Dr. Pemmaraju serves as the co-course director for the Leukemia rotation and is a member of the Fellowship Educational Steering Committee at MD Anderson. He has also published his original work in the field of medical humanities (both prose and poetry) in peer-reviewed medical journals, and is an active member of the medical social media community; he is the founder of #mpnsm, or myeloproliferative neoplasms in social media, a Twitter-based community focused on discussion of topics of interest to MPN researchers, providers and patients during medical conferences and throughout the year. Dr. Pemmaraju has been a consultant or received research support from Incyte, Novartis, LFB, Stemline, Cellectis and Roche Diagnositcs.